Skip to contentN
Neogenomics Inc
N
NEONeogenomics Inc Q1 2021 · 10-Q
Revenue$115.53M$115.53M+9.0% vs Q1 2020 Net Income-$22.11M-$22.11MN/M vs Q1 2020 EPS Diluted-$0.19-$0.19N/M vs Q1 2020 Gross Profit$41,574,000−10.3% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Neogenomics Inc · CIK 1077183 · Engraved from SEC EDGAR
Operating Cash Flow$2,210,000N/M Free Cash Flowderived-$13,621,000N/M Margins · derivedGross margin36.0%−7.7 pt vs Q1 2020
Operating margin-13.1%−8.1 pt vs Q1 2020
Net margin-19.1%−12.6 pt vs Q1 2020
ended Mar 31, 2021 · filed May 6, 2021 · 36 d after period end